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ABSTRACT
This study evaluated the impact of heptavalent pneumococcal conjugate vaccine (HPCV) on invasive
pneumococcal disease (IPD) in children aged £ 5 years in Barcelona, Spain. The incidence of IPD,
vaccine uptake and prevalence of nasopharyngeal colonisation were analysed in two different periods:
1999–2001 (pre-licence period), and 2002–2004 (post-licence period). In total, 121 cases of IPD were
identified. The overall incidence of IPD decreased from 96.9 cases ⁄ 100 000 to 90.6 cases ⁄ 100 000
(OR 0.93, 95% CI 0.69–1.26, p 0.71) between the two periods. The proportion of cases caused by non-
vaccine-related serotypes (NVS) increased from 21% to 43.7% (OR 2.9, 95% CI 1.2–7, p 0.01). IPD was
diagnosed in seven vaccinated children, six of whom were infected by NVS. There was a trend of
diminishing prevalence of resistance to penicillin and macrolides in 2002–2004. The incidence of
empyema increased from 1.7 to 8.5 ⁄ 100 000 (OR 4.5, 95% CI 0.91–18, p 0.06). The rate of vaccination
ranged from 4.8% to 34%. It was concluded that the rates of IPD in this area did not decrease following
the introduction of HPCV. The low uptake of vaccine and the greater proportion of colonisation ⁄ infec-
tion by NVS probably explain these findings. A trend of increasing empyema was also apparent. A
decrease in the prevalence of penicillin and macrolide resistance paralleled the progressive uptake of
vaccine.
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INTRODUCTION
Streptococcus pneumoniae is responsible for a wide
spectrum of infections in young children, ranging
from acute otitis media to sepsis. Since the late
1990s, following the introduction of Haemophilus
influenzae type b conjugate vaccine, pneumococci
have become the most important cause of acute
community-acquired meningitis among young
children. Moreover, increasing resistance to peni-
cillin and other drugs among pneumococci has
complicated the empirical treatment of these
infections. Hence, there is increasing interest in
the development of an immunogenic vaccine for
use in this age group.
Heptavalent pneumococcal polysaccharide
conjugate vaccine (HPCV) has been available
in the USA since 2000, and is recommended for
all children aged £ 5 years. HPCV has demon-
strated its ability to reduce the incidence of
invasive pneumococcal disease (IPD) caused by
vaccine-related serotypes in children aged
< 2 years [1,2]. HPCV is also highly effective in
preventing pneumonia [3], and has substantially
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reduced the number of cases of recurrent acute
otitis media and the necessity for placement of
tympanostomy tubes in healthy infants [4,5].
HPCV has also reduced nasopharyngeal coloni-
sation by vaccine-related serotypes among vac-
cinated individuals [6,7]. Interestingly, it has
been shown that use of pneumococcal conjugate
vaccine may also be reducing the incidence of
disease in adults [1], and significant declines in
resistance to penicillin and macrolides have
been noted [8] (43rd Interscience Conference
on Antimicrobial Agents and Chemotherapy,
abstract G-2045).
HPCV was licensed for use in Spain in 2001. It
is well-known that the vaccine’s efficacy is influ-
enced by the rate of vaccine uptake, by the
number of carriers of pneumococcal serotypes
not included in the vaccine, and probably by the
use of antibiotics in a specific area [1]. The aim of
the present study was to evaluate the impact of




The health district of Terrassa is in the province of Barcelona,
and includes four municipalities that contain c. 23 000 children
aged < 5 years, among a total population of 350 000 inhabi-
tants. The paediatric population is served by two acute-care
hospitals, Hospital Mu´tua de Terrassa (HMT) and Consorci
Sanitari de Terrassa, and by nine primary care centres that
refer children with potentially severe medical conditions to the
paediatric emergency departments of the two hospitals; in
addition, private paediatricians in the area send their patients
to the hospitals referred to above.
Prevalence of vaccine uptake studies
Vaccination with HPCV is not yet compulsory in Spain, but is
highly recommended by paediatricians in the Barcelona area.
Vaccine uptake, prevalence of nasopharyngeal colonisation
and overall incidence of IPD were analysed in two different
periods: 1999–2001 (pre-licence period), and 2002–2004 (post-
licence period). Data were obtained from three different
sources: (1) during January and February 2005, 181 randomly
selected parents of children aged £ 5 years who had attended
the Emergency Department of HMT (for any reason) were
interviewed to ascertain the number of children who had
received at least two doses of HPCV; (2) a study of HPCV
uptake was carried out in a primary care centre in the area that
had computerised medical records with dates and doses of
vaccination; in this centre, the paediatric population examined
during the first trimester of 2005 comprised 1024 and 1742
children aged < 2 and < 5 years, respectively; and (3) data were
obtained from the manufacturer and distributor of HPCV
(Wyeth Lederle, Madrid, Spain) concerning the total number
of doses of HPCV sold between 2002 and 2004 in the four
municipalities in which the two hospitals and the primary care
centres were based.
Nasopharyngeal colonisation study
Between 2001 and 2003, S. pneumoniae nasopharyngeal colo-
nisation was studied in children aged £ 5 years who attended
the emergency department of one of the participating
hospitals (HMT). After informed parental consent, nasopha-
ryngeal samples of children were taken with a trans-nasal
alginated swab and were processed immediately upon arrival
at the microbiology laboratory. The swabs were added to
20 mL of brain–heart infusion broth and shaken until there
was visible turbidity. The suspension was then inoculated on
blood agar plates containing colistin and nalidixic acid
(bioMe´rieux, Marcy l’Etoile, France) and incubated at 37C
in CO2 5% v ⁄v for a maximum of 48 h. Following incubation,
the identification of each isolate was confirmed by the
optochin disk test. Viable isolates of S. pneumoniae were
serogrouped by the National Centre of Microbiology,
Majadahonda, Madrid, Spain. Penicillin susceptibility was
determined by agar dilution using the MIC breakpoints
established by the CLSI (formerly NCCLS). Isolates that were
intermediately-resistant or resistant to penicillin were classi-
fied as non-susceptible.
Estimation of incidence of IPD
All isolates of S. pneumoniae recovered from children with
IPD aged £ 5 years in the area between 1999 and 2004 were
studied. A case of IPD was defined by a positive culture of
S. pneumoniae from a normally sterile body fluid. During the
period 1999–2003, blood cultures were processed with the
automated Vital system (bioMe´rieux), after which the BacT-
Alert system (bioMe´rieux) was used. Pleural fluid and
cerebrospinal fluid were cultured by conventional methods.
Serotypes were classified as vaccine serotypes (VS) (4, 6B,
9V, 14, 18C, 19F and 23F), vaccine-related serotypes (VRS)
(6A, 19A, 23A, etc.) or non-vaccine serotypes (NVS). Annual
incidence rates were calculated from IPD case numbers (as
numerator) and local Census Bureau estimates (as denom-
inator). Annual incidence rates were compared between the
pre-licence period (1999–2001) and the post-licence period
(2002–2004).
Medical records for all patients with IPD who had been
vaccinated with two or more doses of HPCV were reviewed.
Vaccine failure was defined as invasive disease caused by a VS
in a vaccinated patient. Data collected included demogra-
phical, clinical and microbiological variables, immunodeficien-
cies, previous antibiotic therapy and outcome.
Statistical analysis
Percentages were used to analyse qualitative variables; means
and standard deviations were used to evaluate quantitative
data in the descriptive analysis. In the bivariate analysis,
Student’s t-test was used to compare means. The chi-square
and Fisher’s exact test were used to compare the proportion
of the population aged £ 5 years who had invasive disease in
the years following the introduction of the vaccine (2002–
2004) with the proportion in the pre-licence period (1999–
2001).
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RESULTS
Vaccine uptake
The prevalence study performed in one of the
participating hospitals (HMT) included 181 chil-
dren seen in the emergency department during
January and February 2005; vaccine uptake
among children aged £ 5 years was 33%. The
results obtained in the primary care centre during
the first trimester of 2005 showed that 230 (22.3%)
of 1024 children aged < 2 years, and 247 (14.1%)
of 1742 children aged < 5 years, had been vacci-
nated. Finally, after taking into account the total
number of doses of vaccine sold in the area, and
using the total population aged £ 2 years as the
denominator, the percentage of vaccinated chil-
dren ranged from 4.8% in 2002 to 34% in 2004.
S. pneumoniae serotypes and nasopharyngeal
colonisation among children aged £ 5 years
Between 2001 and 2003, 134 children were includ-
ed in the study of nasopharyngeal colonisation,
with 67 (50%) carrying S. pneumoniae in their
nasopharynx. Of the children studied, 17 (12.7%)
were aged < 12 months, 35 (26.1%) were aged 13–
24 months, and 82 (61%) were aged > 24 months;
70 (52.2%) were male. The most common sero-
types isolated were 6A, 9V, 14, 19 and 11. When
the entire cohort of colonised children was
considered, 22% (15 ⁄ 67) were colonised by VRS,
34% (23 ⁄ 67) by VS, and 43% (29 ⁄ 67) by NVS.
Invasive pneumococcal disease
Between 1999 and 2004, 121 cases of IPD
were identified in children aged £ 5 years. The
overall incidence of IPD decreased from
96.9 cases ⁄ 100 000 children during 1999–2001 to
90.6 cases ⁄ 100 000 during 2002–2004 (OR 0.93,
95% CI 0.69–1.26, p 0.71). The main clinical diag-
noses among the cases of IPD are shown in Table 1.
Invasive pneumococcal disease among
vaccinated children
During 2002–2004, IPD was diagnosed in seven
vaccinated children, all of whom were aged
between 6 and 36 months and had received at
least two doses of HPCV according to the sched-
ule recommended by the Vaccines Advisory
Committee of the Sociedad Espan˜ola de Pediatrı´a.
NVS were isolated from all but one patient
(patient 7, Table 2), who developed IPD caused
by serotype 6A, which is considered to be a VRS.
The outcome was favourable in all seven cases.
Neither humoral nor cellular immunodeficiencies,
or complement dysfunction, were found in any of
these children. The incidence of empyema in-
creased from 1.7 ⁄ 100 000 to 8.5 ⁄ 100 000 (OR 4.5,
95% CI 0.91–18, p 0.06). Pleural isolates all be-
longed to serotype 1, with the single exception of
a case caused by serogroup 4 in the post-licence
period. The incidence of meningitis fell by 68%,
from 3.4 ⁄ 100 000 to 1.4 ⁄ 100 000 (OR 0.5,
95% CI 0.09–3, p 0.68).
Serotype prevalence and antimicrobial
susceptibilities among IPD isolates
The proportion of infections caused by NVS
increased from 21% during 1999–2000 to 43.7%
during 2002–2004 (OR 2.9, 95% CI 1.2–7, p 0.01).
The changes in prevalence of serogroups ⁄ sero-
types between the two periods are shown
in Fig. 1. Serotype 1 was the most prevalent,
followed by serotypes 14, 19, 6A, 6B and 23F.
Penicillin-non-susceptible S. pneumoniae iso-
lates from children with IPD aged £ 5 years
decreased from 49% in 1999–2001 to 42% in
2002–2004 (OR 1.3, 95% CI 0.6–2.9, p 0.56). In
addition, erythromycin resistance among isolates
decreased from 52.6% in 1999–2001 to 35.9% in
2002–2004 (OR 1.98, 95% CI 0.89–4.39, p 0.09).
Cefotaxime-susceptible isolates accounted for
96.5% and 95.4% of isolates during 1999–2001
and 2002–2004, respectively (OR 0.7, 95% CI 0.1–
5.7, p not significant).
DISCUSSION
The rates of IPD in the Barcelona area during the
two periods studied (97 and 91 ⁄ 100 000 children
aged £ 5 years, respectively) are higher than those
Table 1. Invasive pneumococcal disease among children
aged £ 5 years during the periods 1999–2001 and 2002–
2004 (cases ⁄ 100 000 children aged £ 5 years)
Disease 1999–2001 2002–2004 OR (95% CI); p
Meningitis 3.4 1.41 0.5 (0.09–3); 0.68
Pneumonia 32.32 31.36 0.98 (0.5–1.6); 1
Empyema 1.7 8.5 4.5 (0.91–18); 0.06
Occult bacteraemia 59.4 49.8 0.83 (0.56–1.23); 0.38
Overall incidence 96.9 91.2 0.93 (0.69–1.26); 0.71
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reported in other areas of Spain (range 33.1–
46 cases ⁄ 100 000) [9,10], and are very similar to
those reported in the USA (72–103 cases ⁄ 100 000)
[11,12]. Similarly, there were higher rates of occult
bacteraemia (50–60 cases ⁄ 100 000 vs. 30 cases ⁄
100 000) and bacteraemic pneumococcal pneu-
monia (31–32 cases ⁄ 100 000 vs. 10 cases ⁄ 100 000)
than those reported in neighbouring areas [10]. In
contrast, the rates of acute meningitis were lower
(1.4–3.4 cases ⁄ 100 000) than those reported in all
other recent Spanish studies (4.6–6.2 ⁄ 100 000)
[10,13]. These differences could be associated
with the fact that the two hospitals in the present
study serve a well-defined population, and have
a systematic practice of drawing blood cultures
from all febrile children seen in the emergency
department at both institutions.
The introduction of HPCV to the area during
2002, with an estimated vaccine uptake of c. 30%,
has not been followed by a significant fall in the
incidence of IPD in the population studied, up to
the end of 2004. The vaccine uptake has been
similar in other areas of Spain. It is likely that the
relatively low percentage of vaccinated children
in the area studied, as compared with rates of
vaccine uptake of > 50% in areas where high
efficacy has been documented, is an important
limiting factor in vaccine effectiveness. The fact
that HPCV vaccination is not compulsory in Spain
explains the current low percentage of vaccine
uptake. However, the relative frequency of VS
and VRS causing IPD in a given area will also
influence the efficacy of HPCV, as will the
distribution of serotypes among the nasopharyn-
geal isolates. In the present study, 43% of colo-
nised children aged £ 5 years yielded serotypes
that were unrelated to those represented in the
HPCV. This distribution differs from that des-
cribed among children in the USA, but is similar
to that found in other areas where vaccine
coverage is limited. Thus, in South America,
Africa and Oceania, the seven vaccine serotypes
represent 50–70% of all cases of IPD [14]. As in
previous studies, the present data indicate that
vaccine coverage against the serotypes causing
IPD among children aged £ 2 years in Spain is
even lower. Thus, Fenoll and Casal [15] reported
that the coverage afforded by HPCV in 2000 was
74%, decreasing to 54% in 2003, while a prelim-
inary report revealed only 40% coverage in 2004
[16].
Analysis of the IPD cases in the present study
showed a clear substitution of VS and VRS by
NVS between the pre-licence and post-licence
periods. NVS as a cause of IPD increased in this
population from 21% to 43% (a 49% increase).
This phenomenon was described in the initial
studies on the impact of HPCV [1,2,16–20]. In
these studies, the decrease in the incidence of
infection caused by VS, following the introduction
Table 2. Cases of invasive pneumoccocal disease among children aged £ 5 years who received two or more doses of
heptavalent pneumococcal conjugate vaccine during the first 2 years following the introduction of the vaccine
Case Age (months) Gender Clinical syndrome Vaccine Serotype Outcome
1 18 Female Pneumonia + empyema 3 doses 5 Favourable
2 36 Female Pneumonia + bacteraemia 2 doses 1 Favourable
3 13 Female Occult bacteraemia 3 doses 33 Favourable
4 35 Female Bacteraemia + septic shock 4 doses 12 Favourable
5 17 Male Occult bacteraemia 2 doses 38 Favourable
6 21 Male Meningitis + bacteraemia 3 doses 7 Favourable
7 6 Male AOM + bacteraemia 2 doses 6A Favourable




















Fig. 1. Changes in prevalence of
the most common serotypes causing
invasive pneumococcal disease in
children aged < 5 years during
1999–2001 and 2002–2004.
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of HPCV, generated an increase in NVS that
ranged from 27% to 37% [1,2]. The present study
did not determine whether this inversion in the
frequency of distribution of serotypes was the
result of an increase in infections caused by NVS
or of capsular switching [21,22]. The high per-
centage of children colonised with NVS, and the
clear substitution of VS and VRS by NVS between
the pre- and post-licence periods, is a matter of
concern. Further studies are needed urgently to
confirm these trends and to better delineate the
potential limitations of HPCV in Spain.
Seven children vaccinated with at least two
doses of HPCV had IPD, giving an estimated
incidence among vaccinated children of 0.1%.
None of the serotypes causing disease in these
children were included in the vaccine, and all
seven had infections caused by strains that were
susceptible to penicillin. Interestingly, one child
developed IPD, caused by an isolate of serotype
6A, less than 6 weeks after the second dose of
vaccine (administered at an age of 5 months).
Although serotype 6A is a VRS, it is likely that the
humoral response is still poor at this age. In fact,
the response is not homogeneous for all vaccine
serotypes, with serotypes 9 and 6 being those
associated with higher vaccine failure rates
[2,18,23].
There was a trend toward a reduction in
penicillin resistance among the invasive isolates
causing IPD during 2002–2004; this was even
more noticeable with the macrolides, for which
the prevalence of resistance decreased from
52.6% to 35.9%. Similar trends have been ob-
served in other recent surveys [8,24]. In addition
to the possible impact of HPCV, the progressive
and continued decrease in overall antibiotic
consumption in Spain, and an increase in the
use of fluoroquinolones for treating respiratory
tract infections [24], are probably playing a
complementary role. In this context, a prelimin-
ary report has described a recent Spanish survey
showing a significant reduction of resistance to
penicillin in pneumococci coinciding with a
reduction in the frequency of isolation of clones
Spain6B-2 and Spain23F-1 (44th Interscience Con-
ference on Antimicrobial Agents and Chemother-
apy; abstract C2-827). Fortunately, NVS are
generally sensitive to penicillin, albeit with some
exceptions, notably serotype 35B, which is usu-
ally associated with penicillin resistance [25].
Indeed, there has already been a preliminary
report of an increase in non-penicillin-resistant
serotypes in areas with high rates of vaccination
with HPCV (43rd Interscience Conference on
Antimicrobial Agents and Chemotherapy; ab-
stract G-890). This is a good reason to continue
active surveillance programmes focused on the
changing distribution of serotypes. The signifi-
cant increase in the incidence of empyema prob-
ably results from a combination of the factors
referred to above, and especially from the emer-
gence of non-vaccine serotypes. The same phe-
nomenon has been observed in the USA [26].
In summary, the rates of IPD in the Barcelona
area during the study periods were higher than
those reported in other areas of Spain, and have
not decreased significantly following the intro-
duction of HPCV. The low vaccine uptake and a
greater proportion of NVS colonising and ⁄ or
infecting children help to explain these findings.
An increase in the incidence of empyema also
became apparent. A trend toward a decreasing
prevalence of penicillin and macrolide resistance
among pneumococci was detected in parallel with
a progressive increase in vaccine uptake, although
other factors could also have contributed to this
phenomenon.
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